Felvizumab

Names

[ Name ]:
Felvizumab

Biological Activity

[Description]:

Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV[1][2].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> RSV

[Target]

EC50: 0.49 μg/mL (RSV Type A in microneutralization assay), 0.95 μg/mL (RSV Type A in fusion inhibition assay)[2]

[In Vitro]

Felvizumab (RSHZ19) (2 h or 4 h) 抑制 RSV A 型，微量中和试验中 EC50 为 0.49 ± 0.37 μg/mL，融合抑制试验中 EC50 为 0.95 ± 0.13 μg/mL[2]。

[In Vivo]

Felvizumab (RSHZ19) (0.625-5.0 mg/kg; intramuscular injection; once) 在 RSV 感染大鼠模型中对 A 和 B 亚型 RSV 有效[2]。 Animal Model: Cotton rats, RSV infection model[2] Dosage: 0.625, 1.25, 2.5, and 5.0 mg/kg Administration: Intramuscular injection, 1 day before infection Result: Significantly reduced lung RSV titer.

[References]

[1]. Fenton C, et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs. 2004;6(3):177-97.

[2]. Johnson S, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis. 1999 Jul;180(1):35-40.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.